We believe that in hepatic phenotype of DLD deficiency the treatment cornerstone should be prevention/early treatment of metabolic decompensation by avoiding catabolism with sufficient early intravenous glucose intake, if necessary with insulin to avoid lactic acidosis. This evidence concerns the gene INS and pyruvate dehydrogenase E3 deficiency.